RETIN-A GEL Rx
Generic Name and Formulations:
Tretinoin 0.01%, 0.025%; alcohol 90%.
Bausch Health Companies Inc.
- Prostate Cancer and Testosterone Replacement Therapy
- FDA Approves Zykadia for Metastatic NSCLC
- Mechlorethamine Topical Gel Effective in Mycosis Fungoides
- Wound Care Products
- Topical Steroid Medications
- Non-Hodgkin Lymphoma (NHL) Treatment Regimens: Primary Cutaneous B-Cell Lymphoma Treatment Regimens
Indications for RETIN-A GEL:
Apply sparingly at bedtime to clean dry skin; adjust strength and frequency as tolerated and needed.
Not for use in eczema or sunburned skin. Avoid eyes, mouth, angles of nose, mucous membranes, sun, UV light. Discontinue if sensitivity reactions occur. Increased irritation in weather extremes. Gel: flammable. Pregnancy (Cat.C): not recommended. Nursing mothers.
Caution with concomitant topical medication, medicated or abrasive soaps/cleansers, astringents, drying agents, high-alcohol content topical products, spices. Avoid contact with peel of limes. Allow effects of benzoyl peroxide, sulfur, resorcinol, salicylic acid, other topical acne agents to subside before applying.
Local irritation, skin pain, pruritus, pharyngitis, erythema, transient symptom exacerbation or pigmentation changes, dryness, stinging, photosensitivity.
Micro 0.04%, 0.1%—20g, 45g, 50g; 0.08%—50g; Crm—20g, 45g; Gel—15g, 45g; Liq—28mL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes In on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma